(19)
(11)EP 3 725 888 A1

(12)EUROPEAN PATENT APPLICATION

(43)Date of publication:
21.10.2020 Bulletin 2020/43

(21)Application number: 19169841.4

(22)Date of filing:  17.04.2019
(51)International Patent Classification (IPC): 
C12N 15/861(2006.01)
A61K 48/00(2006.01)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME
Designated Validation States:
KH MA MD TN

(71)Applicant: TARGOVAX ASA
0283 Oslo (NO)

(72)Inventors:
  • KURYK, Lukasz
    00180 Helsinki (FI)
  • ERIKSEN, Jon Amund
    3916 Porsgrunn (NO)
  • SKORPIL, Peter
    1447 Drøbak (NO)
  • BURNS, Robert
    Oxford, OX1 5ER (GB)
  • MØLLER, Anne-Sophie
    1358 Jar (NO)

(74)Representative: Boco IP Oy Ab 
Itämerenkatu 5
00180 Helsinki
00180 Helsinki (FI)

  


(54)ONCOLYTIC ADENOVIRAL VECTOR EXPRESSING PEPTIDYLARGININE DEIMINASE AND TISSUE INHIBITOR OF METALLOPROTEINASE


(57) The present invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing peptidylarginine deiminase and TIMP in a cell and increasing anti-tumor effect and induction of specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing transgenes in a cell and increasing anti-tumor effect and generation of specific immune response in a subject.


Description

FIELD OF THE DISCLOSURE



[0001] The present invention relates to cancer therapies. More specifically, the present invention relates to oncolytic adenoviral vectors and cells and pharmaceutical compositions comprising said vectors. The present invention also relates to a use of said vectors in the manufacture of a medicament for treating cancer in a subject and a method of treating cancer in a subject. Furthermore, the present invention relates to methods of producing peptidylarginine deiminase and tissue inhibitors of metalloproteinase in a cell and increasing anti-tumor effect and induction of specific immune response in a subject, as well as uses of the oncolytic adenoviral vector of the invention for producing transgenes in a cell and increasing anti-tumor effect and generation of specific immune response in a subject.

BACKGROUND OF THE DISCLOSURE



[0002] During the last twenty years gene transfer technology has been under intensive examination. The aim of cancer gene therapies is to introduce a therapeutic gene into a tumor cell. These therapeutic genes introduced to a target cell may for example correct mutated genes, suppress active oncogenes or generate additional properties to the cell. Suitable exogenous therapeutic genes include but are not limited to immunotherapeutic, anti-angiogenic, chemoprotective and "suicide" genes, and they can be introduced to a cell by utilizing modified virus vectors or non-viral methods including electroporation, gene gun and lipid or polymer coatings.

[0003] Requirements of optimal viral vectors include an efficient capability to find specific target cells and express the viral genome in the target cells. Furthermore, optimal vectors have to stay active in the target tissues or cells. All these properties of viral vectors have been developed during the last decades and for example retroviral, adenoviral and adeno-associated viral vectors have been widely studied in biomedicine.

[0004] To further improve tumor penetration and local amplification of the anti-tumor effect, selectively oncolytic agents, e.g. conditionally replicating adenoviruses, have been constructed. Oncolytic adenoviruses are a promising tool for treatment of cancers. Tumor cells are killed by oncolytic adenoviruses due to a replication of the virus in a tumor cell, the last phase of the replication resulting in a release of thousands of virions into the surrounding tumor tissues for effective tumor penetration and vascular re-infection. Tumor cells allow replication of the virus while normal cells are spared due to engineered changes in the virus genome, which prevent replication in non-tumor cells.

[0005] In addition to replication mediated cell killing, oncolytic adenoviruses can also be armed with different therapeutic transgenes. This approach combines the advantages of conventional gene delivery with the potency of replication competent agents. One goal of arming viruses is induction of an immune reaction towards the cells that allow virus replication. Virus replication alone, although immunogenic, is normally not enough to induce effective anti-tumor immunity. To strengthen induction of therapeutic immunity, viruses can be armed with stimulatory proteins such as cytokines for facilitation of the introduction of tumor antigens to antigen presenting cells such as dendritic cells, and their stimulation and/or maturation. Introduction of immunotherapeutic genes into tumor cells and furthermore, translation of the proteins, leads to activation of the immune response and efficient destruction of tumor cells. The most relevant immune cells in this regard are natural killer cells (NK), CD4+ T helper cells and cytotoxic CD8+ T-cells.

[0006] More than 50 different serotypes of adenoviruses have been found in humans. Adenovirus serotype 5 (Ad5) is known to cause respiratory diseases and it is the most common serotype studied in the field of gene therapy. In the first Ad5 vectors E1 and/or E3 regions were deleted enabling insertion of foreign DNA to the vectors. Furthermore, deletions of other regions as well as further mutations have provided extra properties to viral vectors, indeed, various modifications of adenoviruses have been suggested for achieving efficient antitumor effects.

[0007] Matrix metalloproteinases (MMPs) are endopeptidases. The MMPs belong to a larger family of proteases known as the metzincin superfamily. these enzymes are capable of degrading all kinds of extracellular matrix proteins. They are known to be involved in the cleavage of cell surface receptors, the release of apoptotic ligands and chemokine/cytokine inactivation. MMPs are also thought to play a major role in cell proliferation, migration (adhesion/dispersion), differentiation, angiogenesis, apoptosis, and host defense.

[0008] The matrix metalloproteinases are inhibited by specific endogenous tissue inhibitors of metalloproteinases (TIMPs), which comprise a family of four protease inhibitors: TIMP1, TIMP2, TIMP3 and TIMP4. Of the four TIMPs, TIMP1 overexpression or TIMP3 silencing is consistently associated with cancer progression or poor patient prognosis.

[0009] In enzymology, a protein-arginine deiminase (PADI) is an enzyme that catalyzes a form of post translational modification called arginine de-imination or citrullination. This enzyme belongs to the family of hydrolases, those acting on carbon-nitrogen bonds other than peptide bonds, specifically in linear amidines. The systematic name of this enzyme class is protein-L-arginine iminohydrolase. This enzyme is also called peptidylarginine deiminase. There are four members in this family, namely PADI1, PADI2, PADI3 and PADI4. PADI1 (peptidyl arginine deiminase 1), an enzyme isolated from Mycoplasma, degrades arginine into its citrulline precursor. It has been shown that deprivation of arginine (tumor starvation) has impact on tumor regression (G1 cell cycle arrest with apoptosis and anti-angiogenesis properties), (melanoma, prostate, hepatocellular carcinoma seems to be a good target). Arginine deiminase is a novel anticancer enzyme that produces depletion of arginine, which is a nonessential amino acid in humans. These tumours that are sensitive to arginine depletion do not express argininosuccinate synthetase, a key enzyme in the synthesis of arginine from citrulline (Feun and Savaraj, 2006, Jahani et al., 2018).

[0010] EP2379586B1 discloses an oncolytic adenoviral vector comprising an adenovirus serotype 5 (Ad5) nucleic acid backbone, a 24 bp deletion (D24) in the Rb binding constant region 2 of adenoviral E1 and a nucleic acid sequence encoding a granulocyte-macrophage colony-stimulating factor (GM-CSF) in the place of the deleted gp19k/6.7K in the adenoviral E3 region. US20160339066A1 discloses to adjunct therapies that include co-administration and co-formulation of a complement inhibitor and/or a lipid emulsion composition with the oncolytic virus. The document also discloses that oncolytic virus, such as adenovirus, can be made to express an anti-metastatic gene, such as TIMP-2. WO2014055960A1 relates to composition containing a nucleic acid encoding a chromophore producing enzyme(s). Anti-metastatic agents, such as TIMP-2, expressed by the oncolytic virus can directly or indirectly inhibit one or more steps of the metastatic cascade.

[0011] Still, more efficient and accurate gene transfer as well as increased specificity and sufficient tumor killing ability of gene therapies are warranted. Safety records of therapeutic vectors must also be excellent. The present invention provides a cancer therapeutic tool with these aforementioned properties by utilizing both oncolytic and immunotherapeutic properties of adenoviruses in a novel and inventive way.

BRIEF DESCRIPTION OF THE DISCLOSURE



[0012] The object of the invention is to provide novel methods and means for achieving the above-mentioned properties of adenoviruses and thus, solving the problems of conventional cancer therapies. More specifically, the invention provides novel methods and means for gene therapy.

[0013] TIMP-2 is known to be able to inhibit tumor growth, invasion, angiogenesis and metastasis in experimental models, which has been associated with their MMP inhibitory activity (Bourboulia et al., 2013, Seo et al., 2003). The present inventors hypothesized that the members of TIMP family as transgenes could contribute in cancer treatment and enhance properties of an oncolytic virus. PADI1 is a potential inhibitor of angiogenesis and tumour growth. The present inventors hypothesized the members of peptidylarginine deiminase family could be highly beneficial in cancer therapy as they can function both as an antiproliferative and an antiangiogenic agent (Park et al., 2003). The present inventors found that the double transgene virus coding for TIMP2 and PADI1 will induce innate and adaptive immune system leading to the development of anti-tumor responses after local administration. Additionally, it was found that the expression of TIMP2 inhibits the MMPs functionality and thus inhibit the tumor growth. PADI1 can eliminate arginine from the tumor microenvironment inhibiting the tumor growth and leading to tumor starvation. The strategy of using the members of TIMP and peptidylarginine deiminase proteins expressed by the oncolytic virus is to utilize different mechanism of actions that should exhibit synergistic anti-tumor effects.

[0014] The double transgene virus was found to be a more efficient model compared to that where both transgenes were encoded by separate viruses but used together. The double transgene simplifies the production process especially in clinical studies over combining two viruses expressing the transgenes separately.

[0015] The present application describes construction of recombinant viral vectors, methods related to the vectors, and their use in tumor cells lines and animal models.

[0016] The present invention relates to an oncolytic adenoviral vector comprising an adenovirus serotype 5 (Ad5) nucleic acid backbone, a 24 bp deletion (D24) in the Rb binding constant region 2 of adenoviral E1 and a nucleic acid sequence encoding peptidylarginine deiminase and a nucleic acid sequence encoding TIMP connected with IRES sequence in adenovirus E3 region. Alternatively, the nucleic acid sequence encoding peptidylarginine deiminase and the nucleic acid sequence encoding TIMP can be connected with P2A sequence. The nucleic acid sequence encoding peptidylarginine deiminase and the nucleic acid sequence encoding TIMP can be at the same place, where GM-CSF was inserted in ONCOS-102, i.e. in the place of deleted gp19k/6.7K in adenovirus E3 region. Alternatively, the nucleic acid sequence encoding peptidylarginine deiminase and the nucleic acid sequence encoding TIMP can be inserted in the place of deleted 2.7kbp in E3 region. Preferably, the vector contains an adenovirus 3 serotype knob replacing the wild type serotype 5 knob (5/3 chimeric). More preferably, the peptidylarginine deiminase is PADI1 and TIMP is TIMP2.

[0017] The present invention further relates to a cell comprising the adenoviral vector of the invention.

[0018] The present invention also relates to a pharmaceutical composition comprising the adenoviral vector of the invention.

[0019] The present invention also relates to a use of the adenoviral vector of the invention in the manufacture of a medicament for treating cancer in a subject.

[0020] The present invention also relates to a method of treating cancer in a subject, wherein the method comprises administration of the vector or pharmaceutical composition of the invention to a subject.

[0021] Furthermore, the present invention also relates to a method of producing peptidylarginine deiminase and TIMP in a cell, wherein the method comprises: a) carrying a vehicle comprising an oncolytic adenoviral vector of the invention to a cell, and b) expressing peptidylarginine deiminase and TIMP of said vector in the cell. Preferably, PADI1 and TIMP2 are expressed.

[0022] Furthermore, the present invention also relates to a method of increasing tumor specific immune response in a subject, wherein the method comprises: a) carrying a vehicle comprising an oncolytic adenoviral vector of the invention to a target cell or tissue, b) expressing peptidylarginine deiminase and TIMP of said vector in the cell, and c) increasing amount of cytotoxic T cells and/or natural killer cells in said target cell or tissue. Preferably, PADI1 and TIMP2 are expressed.

[0023] Still, the present invention also relates to a use of the oncolytic adenoviral vector of the invention for producing peptidylarginine deiminase and TIMP in a cell. Preferably, PADI1 and TIMP2 are produced.

[0024] Still, the present invention also relates to a use of the oncolytic adenoviral vector of the invention for increasing tumor specific immune response in a subject.

[0025] The present invention provides a tool for treatment of cancers, some of which are refractory to current approaches. Also, restrictions regarding tumor types suitable for treatment remain few compared to many other treatments. In fact, all solid tumors may be treated with the proposed invention. Larger tumors by mass and more complex tumors can be treated by using the present invention. The treatment can be given intratumorally, intracavitary, intravenously and in a combination of these. The approach can give systemic efficacy despite local injection. The approach can also eradicate cells proposed as tumor initiating ("cancer stem cells").

BRIEF DESCRIPTION OF THE DRAWINGS



[0026] 

Figure 1 illustrates the shuttle plasmid constructions for the shuttle plasmids for pTGX-07, -09 and -10.

Figure 2 illustrates the shuttle plasmid constructions for the shuttle plasmid for pTGX-12 (PADI1-IRES-TIMP2).

Figure 3 illustrates the cosmid constructions for TGX-07, TGX-09, TGX-10 and TGX-12.

Figure 4 shows TGX-07 virus structure. The virus contains the 24-bp deletion in E1A CR2 (E1A Conserved Region 2 (CR2) with a 24-bp deletion that removed the strongest of two binding sites in E1A for Rb protein (LTCHEAGF), location: 907-951bp), expresses the Ad5/3 hybrid fiber (location: 30,721 - 32,484bp) and codes for the functional TIMP2 protein (functional expression cassette, location: 28,371 - 29,033bp).

Figure 5 shows TGX-09 virus structure. The virus contains the 24-bp deletion in E1A CR2 (E1A Conserved Region 2 (CR2) with a 24-bp deletion that removed the strongest of two binding sites in E1A for Rb protein (LTCHEAGF), location: 907-951bp), expresses the Ad5/3 hybrid fiber (location: 32,050 - 33,813bp) and codes for the functional PADI1 protein (functional expression cassette, location: 28,371 - 30,362bp).

Figure 6 shows TGX-10 virus structure. The virus contains the 24-bp deletion in E1A CR2 (E1A Conserved Region 2 (CR2) with a 24-bp deletion that removed the strongest of two binding sites in E1A for Rb protein (LTCHEAGF), location: 907-951bp), expresses the Ad5/3 hybrid fiber (location: 32,776 - 34,539bp) and codes for the functional PADI1 (functional expression cassette, location: 28,371 - 30,359bp) and TIMP-2 protein (functional expression cassette, location: 30,426 - 31,088bp) connected by P2A sequence.

Figure 7 shows TGX-12 virus structure. The virus contains the 24-bp deletion in E1A CR2 (E1A Conserved Region 2 (CR2) with a 24-bp deletion that removed the strongest of two binding sites in E1A for Rb protein (LTCHEAGF), location: 907-951bp), expresses the Ad5/3 hybrid fiber (location: 32,525-34,288bp) and codes for the functional PADI1 (functional expression cassette, location: 28,904-30,895bp) and TIMP-2 protein (functional expression cassette, location: 31,506-32,163bp)-SV40pA connected by IRES sequence under CMC(CuO) promoter.

Figure 8. Figure 8 a) shows the effects of tested oncolytic adenoviruses on viability of human melanoma cell line Sk-Mel-28 at the concentration of 1000 VP/cell at 72 hours post infection. Absorbance of untreated cells is expressed as 100% and absorbance of treated cells is expressed as a percentage of absorbance of untreated cells. Results are expressed as mean +/- SEM. Figure 8 b) illustrates the effects of tested oncolytic adenoviruses on viability of human melanoma cell line Sk-Mel-28 at the concentration of 10 VP/cell after 72 hours post infection. Absorbance of untreated cells is expressed as 100% and absorbance of treated cells is expressed as a percentage of absorbance of untreated cells. Results are expressed as mean +/- SEM.

Figure 9. Figure 9a) shows the effects of tested oncolytic adenoviruses on viability of human melanoma cell line A2058 at the concentration of 1 VP/cell at 72 hours post infection. Absorbance of untreated cells is expressed as 100% and absorbance of treated cells is expressed as a percentage of absorbance of untreated cells. Results are expressed as mean +/- SEM. Figure 9 b) shows the effects of tested oncolytic adenoviruses on viability of human melanoma cell line A375 at the concentration of 10 VP/cell at 72 hours post infection. Absorbance of untreated cells is expressed as 100% and absorbance of treated cells is expressed as a percentage of absorbance of untreated cells. Results are expressed as mean +/- SEM.

Figure 10. Figure 10 a) illustrates the effect of oncolytic viruses on A2058 right flank tumor growth in BALB/c nude model. Results are expressed as mean +/- SEM. n=1-8 per group. Tumor volume difference is shown from Day 12 to Day 47. Figure 10 b) shows the effect of oncolytic viruses on A2058 left flank tumor growth in BALB/c nude model. Results are expressed as mean +/- SEM. n=1-8 per group. Tumor volume difference is shown from Day 12 to Day 47. Figure 10 c9 shows the effect of oncolytic viruses on A2058 right and left flanks tumor growth in BALB/c nude model. Results are expressed as mean +/- SEM. n=1-8 per group. Tumor volume difference is shown from Day 12 to Day 47. Figure 10 d) shows the body weight difference over time, after tumor cell engraftment. n=1-8 per group, results represent mean +/- SEM. Body weight difference is shown from Day 12 to Day 47.

Figure 11. Figure 11 a) shows the effect of oncolytic viruses on A2058 right flank tumor growth in humanized melanoma mouse model. Results are expressed as mean +/- SEM. n=1-8 per group. Tumor volume difference is shown from Day 12 to Day 28. Figure 11 b) illustrates the effect of oncolytic viruses on A2058 left flank tumor growth in humanized melanoma mouse model. Results are expressed as mean +/- SEM. n=1-8 per group. Tumor volume difference is shown from Day 12 to Day 28. Figure 11 c) illustrates the effect of oncolytic viruses on A2058 right and left flank tumor growth in humanized melanoma mouse model. Results are expressed as mean +/- SEM. n=1-8 per group. Tumor volume difference is shown from Day 12 to Day 28.

Figure 12. Figure 12 a) shows the results of an abscopal effect study. Effect of oncolytic viruses on A2058 right flank tumor growth (treated flank) in humanized melanoma mouse model. Results are expressed as mean +/- SEM. n=1-6 per group. Tumor volume difference is shown from Day 12 to Day 42. Figure 12 b) shows the results of an abscopal effect study. Effect of oncolytic viruses on A2058 left flank tumor growth (non-treated flank) in humanized melanoma mouse model. Results are expressed as mean +/- SEM. n=1-6 per group. Tumor volume difference is shown from Day 12 to Day 42.


SEQUENCE LISTING



[0027] 

Sequence ID NO: 1. A nucleic acid sequence encoding an oncolytic adenoviral vector Ad5/3-D24-CMV(CuO)PADI1-IRES-TIMP2-SV40pA (TGX-12) comprising the 24-bp deletion in E1A CR2 (E1A Conserved Region 2 (CR2) with a 24-bp deletion that removed the strongest of two binding sites in E1A for Rb protein (LTCHEAGF), location: 907-951bp), expresses the Ad5/3 hybrid fiber (location: 32,776 - 34,539bp) and codes for the functional PADI1 (functional expression cassette, location: 28,371 - 30,359bp) and TIMP-2 protein (functional expression cassette, location: 30,426 - 31,088bp).

Sequence ID NO: 2 A nucleic acid sequence encoding an oncolytic adenoviral vector Ad5/3-D24-PADI1-P2A-TIMP2 (TGX-10) The virus contains the 24-bp deletion in E1A CR2 (E1A Conserved Region 2 (CR2) with a 24-bp deletion that removed the strongest of two binding sites in E1A for Rb protein (LTCHEAGF), location: 907-951bp), expresses the Ad5/3 hybrid fiber (location: 32,776 - 34,539bp) and codes for the functional PADI1 (functional expression cassette, location: 28,371 - 30,359bp) and TIMP-2 protein (functional expression cassette, location: 30,426 - 31,088bp).

Sequence ID NO: 3. A nucleic acid sequence encoding an oncolytic adenoviral vector Ad5/3-D24-PADI1 (TGX-09) comprising the 24-bp deletion in E1A CR2 (E1A Conserved Region 2 (CR2) with a 24-bp deletion that removed the strongest of two binding sites in E1A for Rb protein (LTCHEAGF), location: 907-951bp), expresses the Ad5/3 hybrid fiber (location: 32,050 - 33,813bp) and codes for the functional PADI1 protein (functional expression cassette, location: 28,371 - 30,362bp).

Sequence ID NO: 4. A nucleic acid sequence encoding an oncolytic adenoviral vector Ad5/3-D24-TIMP2 (TGX-07), comprising the 24-bp deletion in E1A CR2 (E1A Conserved Region 2 (CR2) with a 24-bp deletion that removed the strongest of two binding sites in E1A for Rb protein (LTCHEAGF), location: 907-951bp), expresses the Ad5/3 hybrid fiber (location: 30,721 - 32,484bp) and codes for the functional TIMP2 protein (functional expression cassette, location: 28,371 - 29,033bp).

Sequence ID NO: 5. A binding site for Rb protein in E1A.

Sequence ID NO: 6. CR2-D24 (TGX-07).

Sequence ID NO: 7. TIMP2 sequence (TGX-07).

Sequence ID NO: 8. Ad5/3 fiber (TGX-07).

Sequence ID NO: 9. CR2-D24 (TGX-09).

Sequence ID NO: 10. Ad5/3 fiber (TGX-09).

Sequence ID NO: 11. PADI1 (TGX-09).

Sequence ID NO: 12. CR2-D24 (TGX-10).

Sequence ID NO: 13. Ad5/3 fiber (TGX-10).

Sequence ID NO: 14. PADI1 (TGX-10).

Sequence ID NO: 15. P2A (TGX-10).

Sequence ID NO: 16. TIMP2 (TGX-10).

Sequence ID NO: 17. CR2-D24 (TGX-12).

Sequence ID NO: 18. Ad5/3 fiber (TGX-12).

Sequence ID NO: 19. CMV promoter/enhancer (TGX-12).

Sequence ID NO: 20. CuO (TGX-12).

Sequence ID NO: 21. CMV 5'UTR (TGX-12).

Sequence ID NO: 22. PADI1 (TGX-12).

Sequence ID NO: 23. IRES (TGX-12).

Sequence ID NO: 24. TIMP2 (TGX-12).

Sequence ID NO: 25. SV40pA (TGX-12).

Sequence ID NO: 26. Primer sequence 282-13.

Sequence ID NO: 27. Primer sequence 282-14.

Sequence ID NO: 28. Primer sequence 282-15.

Sequence ID NO: 29. Primer sequence 282-16.

Sequence ID NO: 25. Primer sequence 282-21.

Sequence ID NO: 25. Primer sequence 282-22.

Sequence ID NO: 25. Primer sequence 282-23.

Sequence ID NO: 25. Primer sequence 282-24.

Sequence ID NO: 25. Primer sequence 282-25.

Sequence ID NO: 25. Primer sequence 282-42.


DETAILED DESCRIPTION OF THE DISCLOSURE



[0028] The double transgene oncolytic adenoviral vector of the present invention is based on an adenovirus serotype 5 (Ad5) nucleic acid backbone with a 24 bp deletion (D24) in the Rb binding constant region 2 (CR2) of adenoviral E1 and a nucleic acid sequence encoding a peptidylarginine deiminase and a nucleic acid sequence encoding a TIMP in the place of the deleted 2.7kbp in the adenoviral E3 region. In a preferred embodiment of the invention, the adenoviral vector backbone is ONCOS-102 as disclosed in EP2379586B1 but comprising of a nucleic acid sequence encoding peptidylarginine deiminase and a nucleic acid sequence encoding TIMP in the place of GM-CSF/E3 region. These sequences can be connected via IRES or P2A sequence.

[0029] Peptidylarginine deiminase can be PADI1, PADI2, PADI3 or PADI4. Preferably, peptidylarginine deiminase is PADI1. More preferably, peptidylarginine deiminase is human PADI1. TIMP can be TIMP1, TIMP2, TIMP3 or TIMP4. Preferably, TIMP is human TIMP2. More preferably, TIMP is human TIMP2.

[0030] The results of the experiments showed superior effect of double transgene viruses. In in vitro cell viability assay (MTS), double transgene virus coding for PADI1 and TIMP2 (TGX-12) showed anti-cancer superiority over singe transgene viruses TGX-07 (coding for TIMP-2) and TGX-09 (coding for PADI1). Importantly, the double transgene virus showed stronger anticancer effect than the combinatory therapy of TGX-07 plus TGX-09 (Figure 8a). Sign of double transgene anti-cancer superiority was also reported at lower concentration, where double transgene exhibited stronger anti-cancer effect over single transgene viruses (Figure 8b). Similarly, the second construct coding for double transgenes (TGX-10) exhibited stronger anti-cancer effect than single transgene viruses TGX-07, TGX-09 and combinatory treatment (Figures 9a and 9b).

[0031] The combination of single transgene viruses TGX-07 and TGX-09 showed the best anticancer properties in terms of tumor volume reduction comparing to mock and single transgene viruses (Figure 10c). In addition, mice treated with TGX-12 and TGX-07 plus TGX-09 maintained the right tumor volumes below 500 mm3 for all animals until the end of the experiment (Figure 10a).

[0032] Surprisingly, double transgene viruses TGX-10 and TGX-12 along with TGX-07 plus TGX-09 viruses showed synergistic effect as they were able to reduce the tumor volume to a greater extent rather than viruses expressing single transgenes TGX-07 and TGX-09 (Table 2). Also, dose-dependent effect of TGX-12 was observed, as mice treated with higher concentration had greater tumor reduction and anti-cancer superiority was observed for the double transgene virus (Figure 11a, 11b, 11c). Surprisingly, mice treated with TGX-12 into only right flank showed abscopal effect as the re-challenged tumor on the left flank exhibited inhibited, low kinetic growth (Figures 12a and 12b), which is most likely due to development of protective immune memory cells.

[0033] Compared to a wild type adenovirus genome, the adenoviral vector of the invention lacks 24 base pairs from CR2 in E1 region, specifically in E1A region, and 2.7kbp deletion in E3 region. 24 base pair deletion (D24) of E1 affects CR2 domain, which is responsible for binding the Rb tumor suppressor/cell cycle regulator protein and thus, allows the induction of the synthesis (S) phase i.e. DNA synthesis or replication phase. pRb and E1A interaction requires eight amino acids 121 to 127 of the E1A protein conserved region, which are deleted in the present invention. Viruses with the D24 are known to have a reduced ability to overcome the G1-S checkpoint and replicate efficiently in cells where this interaction is not necessary, e.g. in tumor cells defective in the Rb-p16 pathway.

[0034] The E3 region is nonessential for viral replication in vitro, but the E3 proteins have an important role in the regulation of host immune response i.e. in the inhibition of both innate and specific immune responses. The E3 deletion along with gp19k/6.7K deletion in E3 refers to a deletion of 2.7kb base pairs from the adenoviral E3A region. In a resulting adenoviral construct, both gp19k and 6.7K genes are deleted. The gp19k gene product is known to bind and sequester major histocompatibility complex I (MHC1) molecules in the endoplasmic reticulum, and to prevent the recognition of infected cells by cytotoxic T-lymphocytes. Since many tumors are deficient in MHC1, deletion of gp19k increases tumor selectivity of viruses {virus is cleared faster than wild type virus from normal cells but there is no difference in tumor cells). 6.7K proteins are expressed on cellular surfaces and they take part in downregulating TNF-related apoptosis inducing ligand (TRAIL) receptor 2.

[0035] An internal ribosome entry site, abbreviated IRES, is an RNA element that allows for translation initiation in a cap-independent manner, as part of the greater process of protein synthesis. In eukaryotic translation, initiation typically occurs at the 5' end of mRNA molecules, since 5' cap recognition is required for the assembly of the initiation complex.

[0036] Instead of these large IRES sequences, a much shorter, self-cleaving 2A peptide can be used. Virus-derived peptide sequences mediate a ribosome-skipping event enables generation of multiple separate peptide products from one mRNA. Peptides from porcine teschovirus-1 (P2A) facilitate expression of multiple transgenes.

[0037] In the present invention, the peptidylarginine deiminase and TIMP transgenes are placed into a 2.7kbp deleted part in the E3 region, under the E3 promoter. This restricts transgene expression to tumor cells that allow replication of the virus and subsequent activation of the E3 promoter. In another embodiment, peptidylarginine deiminase and TIMP are placed under CMV(Cuo) promoter. E3 promoter may be any exogenous or endogenous promoter known in the art, preferably endogenous promoter. In a preferred embodiment of the invention, a nucleic acid sequence encoding peptidylarginine deiminase and TIMP are under the control of the viral E3 promoter. CMV(CuO) promoter contains a copy of the cumate operator (CuO). In "regular" 293 cells and other cell lines, the CuO operator is inactive and transcription takes place from the CMV promoter. In 293-CymR cells, which express the CymR repressor, the CymR repressor binds onto the CuO operator, thereby preventing the transcription of the transgene. Preferably, the transgenes are PADI1 and TIMP2.

[0038] The vectors of the invention may also comprise other modifications than partial deletions of CR2 and E3 and insertion of peptidylarginine deiminase and TIMP sequences as mentioned above. In a preferred embodiment of the invention, all the other regions of the Ad5 vector are of a wild type. In another preferred embodiment of the invention, the E4 region is of a wild type. In a preferred embodiment of the invention, a wild type region is located upstream of the E1 region. "Upstream" refers to immediately before the E1 region in the direction of expression. E1 B region may also be modified in the vector of the invention.

[0039] As used herein, "Ad5/3 chimerism" of the capsid refers to a chimerism, wherein the knob part of the fiber is from Ad serotype 3, and the rest of the fiber is from Ad serotype 5.

[0040] Expression cassettes are used for expressing transgenes in a target, such as a cell, by utilizing vectors. As used herein, the expression "expression cassette" refers to a DNA vector or a part thereof comprising nucleotide sequences, which encode cDNAs or genes, and nucleotide sequences, which control and/or regulate the expression of said cDNAs or genes. Similar or different expression cassettes may be inserted to one vector or to several different vectors. Ad5 vectors of the present invention may comprise either several or one expression cassettes. However, only one expression cassette is adequate. In a preferred embodiment of the invention, the oncolytic adenoviral vector comprises at least one expression cassette. In a preferred embodiment of the invention, the oncolytic adenoviral vector comprises only one expression cassette.

[0041] A cell comprising the adenoviral vector of the invention may be any cell such as a eukaryotic ceil, bacterial cell, animal cell, human cell, mouse cell etc. A cell may be an in vitro, ex vivo or in vivo cell. For example, the cell may be used for producing the adenoviral vector in vitro, ex vivo or in vivo, or the cell may be a target, such as a tumor cell, which has been infected with the adenoviral vector.

[0042] In a method of producing peptidylarginine deiminase and TIMP transgenes in a cell, a vehicle comprising the vector of the invention is carried into a cell and furthermore peptidylarginine deiminase and TIMP transgenes are expressed and the protein is translated and secreted in a paracrine manner. "A vehicle" may be any viral vector, plasmid or other tool, such as a particle, which is able to deliver the vector of the invention to a target cell. Any conventional method known in the art can be used for delivering the vector to the cell.

[0043] Tumor specific immune response may be increased in a subject by the present invention. T helper and cytotoxic T cells and/or natural killer cells are stimulated, produced and targeted because of the construct properties.

[0044] The recombinant Ad5 vectors of the invention have been constructed for replication competence in cells, which have defects in the Rb-pathway, specifically Rb-p16 pathway. These defective cells include tumor cells in animals and humans. In a preferred embodiment of the invention, the vector is capable of selectively replicating in cells having defects in the Rb-pathway. As used herein "defects in the Rb-pathway" refers to mutations and/or epigenetic changes in any genes or proteins of the pathway. Due to these defects, tumor cells overexpress E2F and thus, binding of Rb by E1A CR2, that is normally needed for effective replication, is unnecessary.

[0045] Any cancers or tumors, including both malignant and benign tumors as well as primary tumors and metastasis may be targets of gene therapies. In a specific embodiment of the invention the cancer is any solid tumor. In a preferred embodiment of the invention, the cancer is selected from a group consisting of nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, Hp cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer and tonsil cancer.

[0046] A pharmaceutical composition of the invention comprises at least one type of the vectors of the invention. Furthermore, the composition may comprise at least two or three different vectors of the invention. In addition to the vector of the invention, a pharmaceutical composition may also comprise any other vectors, such as other adenoviral vectors, other therapeutically effective agents, any other agents such as pharmaceutically acceptable carriers, buffers, excipients, adjuvants, antiseptics, filling, stabilising or thickening agents, and/or any components normally found in corresponding products.

[0047] The pharmaceutical composition may be in any form, such as solid, semisolid or liquid form, suitable for administration. A formulation can be selected from a group consisting of, but not limited to, solutions, emulsions, suspensions, tablets, pellets and capsules.

[0048] The effective dose of vectors depends on at least the subject in need of the treatment, tumor type, location of the tumor and stage of the tumor. The dose may vary for example from about 10e8 viral particles (VP) to about 10e14 VP, preferably from about 5x10e9 VP to about 10e13 VP and more preferably from about 8x10e9 VP to about 10e12 VP. In one specific embodiment of the invention the dose is in the range of about 5x10e10 - 5x10e11 VP.

[0049] The vector or pharmaceutical composition of the invention may be administered to any eukaryotic subject selected from a group consisting of plants, animals and human beings, in a preferred embodiment of the invention, the subject is a human or an animal. An animal may be selected from a group consisting of pets, domestic animals and production animals.

[0050] Any conventional method may be used for administration of the vector or composition to a subject. The route of administration depends on the formulation or form of the composition, the disease, location of tumors, the patient, comorbidities and other factors. In a preferred embodiment of the invention, the administration is conducted through an intratumoral, intramuscular, intra-arterial, intravenous, intrapleural, intravesicular, intracavitary or peritoneal injection, or an oral administration.

[0051] Only one administration of oncolytic adenoviral vectors of the invention may have therapeutic effects. However, in a preferred embodiment of the invention, oncolytic adenoviral vectors or pharmaceutical compositions are administered several times during the treatment period. Oncolytic adenoviral vectors or pharmaceutical compositions may be administered for example from 1 to 10 times in the first 2 weeks, 4 weeks, monthly or during the treatment period. In one embodiment of the invention, administration is done three to seven times in the first 2 weeks, then at 4 weeks and then monthly. In a specific embodiment of the invention, administration is done four times in the first 2 weeks, then at 4 weeks and then monthly. The length of the treatment period may vary, and for example may last from two to 12 months or more.

[0052] The gene therapy of the invention is effective alone, but combination of adenoviral gene therapy with any other therapies, such as traditional therapy, may be more effective than either one alone. For example, each agent of the combination therapy may work independently in the tumor tissue, the adenoviral vectors may sensitize cells to chemotherapy or radiotherapy and/or chemotherapeutic agents may enhance the level of virus replication or effect the receptor status of the target cells. The agents of combination therapy may be administered simultaneously or sequentially.

[0053] As used herein, the term "immune checkpoint inhibitor" or "checkpoint inhibitor" refers to molecules that totally or partially reduce, inhibit, interfere with or modulate one or more checkpoint proteins. Checkpoint proteins regulate T-cell activation or function. Central to the immune checkpoint process are the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) immune checkpoint pathways. The CTLA-4 and PD-1 pathways are thought to operate at different stages of an immune response. CTLA-4 is considered the "leader" of the immune checkpoint inhibitors, as it stops potentially autoreactive T cells at the initial stage of naive T-cell activation, typically in lymph nodes. The PD-1 pathway regulates previously activated T cells at the later stages of an immune response, primarily in peripheral tissues.

[0054] Inhibition of the immune checkpoint pathways has led to the approval of several new drugs: ipilimumab (anti-CTLA-4; Yervoy®), pembrolizumab (anti-PD-1; Keytruda®), and nivolumab (anti-PD-1; Opdivo®). Also, PD-L1 inhibitors, such as Atezolizumab (MPDL3280), Avelumab (MSB0010718C) and Durvalumab (MEDI4736), are available. These antagonistic antibodies have been associated with objective clinical responses in cancer patients. Antibodies targeting CTLA-4 are already marketed (e.g. Ipilimumab, Yervoy, Bristol-Myers Squibb, BMS) for metastatic melanoma. Antibody therapies with anti PD-L1 (e.g. MPDL3280A, Roche), anti PD-1 (e.g. Nivolumab, BMS) are also ongoing.

[0055] Other immune-checkpoint inhibitors include lymphocyte activation gene-3 (LAG-3) inhibitors, such as IMP321, a soluble Ig fusion protein. Other immune checkpoint inhibitors include B7 inhibitors, such as B7-H3 and B7-H4 inhibitors. In particular, the anti-B7-H3 antibody MGA271. Also included are TIM3 (T-cell immunoglobulin domain and mucin domain 3) inhibitors. In certain embodiments the PD-1 blockers include anti-PD-L1 antibodies. In certain other embodiments the PD-1 blockers include anti-PD-1 antibodies and similar binding proteins such as nivolumab (MDX 1106, BMS 936558, ONO 4538), a fully human IgG4 antibody 30 that binds to and blocks the activation of PD-1 by its ligands PD-L1 and PD-L2; lambrolizumab (MK-3475 or SCH 900475), a humanized monoclonal IgG4 antibody against PD-1 ; CT-011 a humanized antibody that binds PD-1 ; AMP-224 is a fusion protein of B7-DC; an antibody Fc portion; BMS-936559 (MDX- 1105-01) for PD-L1 (B7-H1) blockade. Further examples of PD-L1 inhibitors that can be used in certain embodiments are Atezolizumab (MPDL3280), Avelumab (MSB0010718C) and Durvalumab.

[0056] Preferably, anti-PD-1 antibodies pembrolizumab (Keytruda), and nivolumab (Opdivo) are used in the invention. Also, PD-L1 inhibitors, such as durvalumab can be used in combination with anti-PD-1-antibodies. The preferred checkpoint inhibitors of the present invention are thus those for PD-1 and PD-L1.

[0057] In a preferred embodiment of the invention, the method or use further comprises administration of concurrent radiotherapy to a subject. In another preferred embodiment of the invention, the method or use further comprises administration of concurrent chemotherapy to a subject. As used herein "concurrent" refers to a therapy, which has been administered before, after or simultaneously with the gene therapy of the invention. The period for a concurrent therapy may vary from minutes to several weeks. Preferably the concurrent therapy lasts for some hours.

[0058] Agents suitable for combination therapy include but are not limited to All-trans retinoic acid, Azacitidine, Azathioprine, Bleomycin, Carboplatin, Capecitabine, Cisplatin, Chlorambucil, Cyclophosphamide, Cytarabine, Daunorubicin, Docetaxel, Doxifluridine, Doxorubicin, Epirubicin, Epothilone, Etoposide, Fluorouracil, Gemcitabine, Hydroxyurea, Idarubicin, Imattnib, Mechlorethamine, Mercaptopurine, Methotrexate, Mitoxantrone, Oxaliplatin, Paclitaxel, Pemetrexed, Temozolomide, Teniposide, Tioguanine, Valrubicin, Vinblastine, Vincristine, Vindesine and Vinorelbine.

[0059] In a preferred embodiment of the invention, the method or use further comprises administration of verapamil or another calcium channel blocker to a subject. "Calcium channel blocker" refers to a class of drugs and natural substances which disrupt the conduction of calcium channels, and it may be selected from a group consisting of verapamil, dihydropyridines, gallopamil, diltiazem, mibefradil, bepridil, fluspirilene and fendiline.

[0060] In a preferred embodiment of the invention, the method or use further comprises administration of autophagy inducing agents to a subject. Autophagy refers to a catabolic process involving the degradation of a cell's own components through the lysosomal machinery. "Autophagy inducing agents" refer to agents capable of inducing autophagy and may be selected from a group consisting of, but not limited to, mTOR inhibitors, P13K inhibitors, lithium, tamoxifen, chloroquine, bafilomycin, temsirolimus, sirolimus and temozolomide. In a specific embodiment of the invention, the method further comprises administration of temozolomide to a subject. Temozolomide may be either oral or intravenous temozolomide.

[0061] In one embodiment of the invention, the method or use further comprises administration of chemotherapy or anti-CD20 therapy or other approaches for blocking of neutralizing antibodies. "Anti-CD20 therapy" refers to agents capable of killing CD20 positive cells and may be selected from a group consisting of rituximab and other anti-CD20 monoclonal antibodies. "Approaches for blocking of neutralizing antibodies" refers to agents capable of inhibiting the generation of anti-viral antibodies that normally result from infection and may be selected from a group consisting of different chemotherapeutics, immunomodulatory substances, corticoids and other drugs. These substances may be selected from a group consisting of, but not limited to, cyclophosphamide, cyclosporin, azathioprine, methylprenisolone, etoposide, CD40L, CTLA4Ig4, FK506 (tacrolismus), IL-12, IFN-gamma, interleukin 10, anti-CD8, anti-CD4 antibodies, myeloablation and oral adenoviral proteins.

[0062] The oncolytic adenoviral vector of the invention induces virion mediated oncolysis of tumor cells and activates human immune response against tumor cells. In a preferred embodiment of the invention, the method or use further comprises administration of substances capable to downregulating regulatory T-cells in a subject. "Substances capable to down- regulating regulatory T-cells" refers to agents that reduce the number of cells identified as T-suppressor or Regulatory T-cells. These cells have been identified as consisting one or many of the following immunophenotypic markers: CD4+, CD25+, FoxP3+, CD127- and GITR+. Such agents reducing T- suppressor or Regulatory T-cells may be selected from a group consisting of anti-CD25 antibodies or chemotherapeutics.

[0063] An object of the invention is an oncolytic adenoviral vector comprising an adenovirus serotype 5 (Ad5) nucleic acid backbone, a 24 bp deletion (D24) in the Rb binding constant region 2 of E1, a nucleic acid sequence encoding peptidylarginine deiminase and a nucleic acid sequence encoding TIMP in the E3 region. The sequences of peptidylarginine deaminase and TIMP can be connected via IRES. According to another embodiment, they can be connected via P2A. Preferably, the sequences of peptidylarginine deaminase and TIMP are located in a gp19k/6.7K or 2.7kbp deletion in the E3 region. Preferably, said vector contains an adenovirus 3 serotype knob replacing the wild type serotype 5 knob (5/3 chimeric). According to a more preferred object of the invention, peptidylarginine deiminase and TIMP are placed under E3 promoter. According to a still more preferred object of the invention, peptidylarginine deiminase and TIMP are placed under CMV(Cuo) promoter. According to one preferred aspect of the invention, the oncolytic adenoviral vector according comprises a native E1 A promoter.

[0064] Preferably, peptidylarginine is PADI1 and TIMP is TIMP2. More preferably, peptidylarginine is human PADI1 and TIMP is human TIMP2.

[0065] Preferably, peptidylarginine deiminase and TIMP are connected with IRES or P2A. Another object of the invention is this oncolytic adenoviral vector further comprising an Ad5/3 chimerism as a capsid modification.

[0066] The nucleotide sequences of vectors show at least 66%, preferably at least 70%, more preferably at least 75%, even more preferably at least 80% identity to SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3 or SEQ ID NO:4. Still more preferably the nucleotide sequences show at least 85% or at least 90% or 95%, more preferably at least 98%, most preferably 99% identity to the nucleic acid sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3 or SEQ ID NO:4.

[0067] A further object of the invention is a method of treating cancer in a human subject in need thereof, wherein a therapeutically effective amount of a pharmaceutical formulation comprising an oncolytic adenovirus comprising nucleotide sequence having at least 70% identity to SEQ ID NO: 1 or SEQ ID NO:2 and a diluent or carrier is administered. In the most preferred embodiment the nucleotide sequence is SEQ ID NO: 1 or SEQ ID NO: 2. Another object of the invention is a method, wherein a therapeutically effective amount of a pharmaceutical formulation comprising a combination of oncolytic adenovirus comprising a nucleotide sequence having at least 70% identity to SEQ ID NO: 3 and oncolytic adenovirus comprising a nucleotide sequence having at least 70% identity to SEQ ID NO: 4 is administered. In the most preferred embodiment, the combination of adenoviruses has nucleotide sequences according to SEQ ID NO: 3 and SEQ ID NO:4.

[0068] One object of the invention is the oncolytic adenoviral vector comprising at least one expression cassette. In another object of the invention, the oncolytic adenoviral vector is capable of selectively replicating in cells having defects in the Rb-pathway.

[0069] Also, a cell comprising the adenoviral vector is one aspect of the invention.

[0070] Another aspect of the invention is a pharmaceutical composition comprising the adenoviral vector of the invention. The adenoviral vector for use in the treatment of cancer or in the manufacture of a medicament for treating cancer in a subject is also an aspect of the invention. The cancer can be selected from a group consisting of nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer and tonsil cancer.

[0071] The subject of the treatment can be a human or an animal.

[0072] The treatment of cancer with adenoviral vector in a subject can be conducted through an intratumoral, intramuscular, intra-arterial, intravenous, intrapleural, intravesicular, intracavitary or peritoneal injection, or an oral administration. The injection or the administration can be conducted several times during the treatment period. Also, an oncolytic adenoviral vector having a different fiber knob of the capsid compared to the vector of the earlier treatment can be used. The treatment of cancer in a subject can further comprise an administration of concurrent radiotherapy and/or concurrent chemotherapy to a subject. The treatment of cancer in a subject can further comprise an administration of a checkpoint inhibitor, verapamil or another calcium channel blocker, autophagy inducing agents, temozolomide, chemotherapy or anti-CD20 therapy or other approaches for blocking of neutralizing antibodies, and/or substances capable to downregulating regulatory T-cells in a subject.

[0073] A method of producing peptidylarginine deiminase and TIMP in a cell in vitro, wherein the method comprises:
  1. a) carrying a vehicle comprising an oncolytic adenoviral vector to a cell, and
  2. b) expressing peptidylarginine deiminase and TIMP of said vector in the cell, is an aspect of the present invention.


[0074] Also, a use of the oncolytic adenoviral vector for producing peptidylarginine deiminase and TIMP2 in a cell in vitro is an aspect of the invention.

[0075] A further object of the invention is a method of treating cancer in a human subject in need thereof, wherein a therapeutically effective amount of a pharmaceutical formulation comprising an oncolytic adenovirus comprising SEQ ID NO: 1 or SEQ ID NO:2 and a diluent or carrier is administered. Another object of the invention is a method, wherein a therapeutically effective amount of a pharmaceutical formulation comprising a combination of oncolytic adenovirus comprising SEQ ID NO: 3 and oncolytic adenovirus comprising SEQ ID NO: 4 is administered. Said methods can further comprise administering an effective amount of an oncolytic adenoviral vector or a pharmaceutical composition comprising the oncolytic adenoviral vector to the subject through intratumoral injection, wherein the oncolytic adenoviral vector comprises the adenovirus according to the invention. In said methods the effective amount of the oncolytic adenoviral vector contains between 5X10e10 - 5X10e11 viral particles. They also induce a specific antitumor immune response, including activation of CD8+ T cells, in tumors expressing the peptidylarginine deiminase and TIMP from the oncolytic adenoviral vector. In said methods for treatment, the oncolytic adenoviral vector can be administered three to seven times in the first two weeks of treatment.

[0076] In said treatment methods cancer can be selected from a group consisting of nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer and tonsil cancer.

[0077] According to one embodiment, the administration of the adenoviral vector or vectors or pharmaceutical composition can be conducted through an intratumoral, intramuscular, intra-arterial, intravenous, intrapleural, intravesicular, intracavitary or peritoneal injection, or an oral administration. According to another embodiment, the adenoviral vector or vectors or pharmaceutical composition can be administered several times during a treatment period. According to a preferred embodiment, concurrent radiotherapy can be administered to the subject. According to a more preferred embodiment, concurrent chemotherapy can be administered to the subject. According to a still more preferred embodiment verapamil or another calcium channel blocker can be administered to the subject.

[0078] In one preferred object of the invention, is a method for treatment with the adenoviral vector or vectors further comprising administering substances capable to downregulating regulatory T-cells in the subject.

[0079] Any method or use of the invention may be either in vivo, ex vivo or in vitro method or use.

[0080] The present invention is illustrated by the following examples, which are not intended to be limiting in any way.

EXAMPLES


Cloning of oncolytic viruses



[0081] Oncolytic viruses were constructed using genetic engineering tools. The construction of oncolytic vectors included the following steps:

1. Shuttle Plasmid Constructions:



[0082] For TGX-07/09/10, the transgenes were inserted into the E3 region at the same location as the GM-CSF coding sequence in vector Ad5/3-D24-GMCSF (see B2379586B1). In that vector, a 0.9 kb BsiWI-Mfel fragment encompassing the E3 6.7K ORF and gp19K ORF was deleted and replaced by the GM-CSF coding sequence. For this cloning, a shuttle plasmid pAd1129-14, which contains the WT E3 region and a hybrid Ad5/3 fiber, was used. The TIMP2, PADI1, PADI1-P2A-TIMP2 sequences were inserted between the BsiWI and Mfel site of pAd1129-14 using standard cloning methods (Figure 1). The identity of the shuttle plasmids was verified by restriction analysis and sequencing.

[0083] For TGX-12, the dicistronic cassettes CMVCuO-PADI1-IRES-TIMP2-SV40pA was inserted in place of the E3 region deleted for most of its genes. Shuttle plasmid pAd1129-27, which contains the Ad5 E3 region and a hybrid Ad5/3 fiber gene, was used. A 2.7 kb BgIII fragment was deleted from the E3 region and replaced with a multiple cloning site. Both dicistronic cassettes were inserted into pAd1129-27 using standard cloning methods (Figure 2). The identity of the plasmids was verified by restriction analysis and sequencing.

2. Cosmid Construction



[0084] The entire genomes of the recombinant adenoviruses were reconstituted in cosmids (Figure 3). Transfection-grade cosmid DNAs were purified and their identity was confirmed by restriction analysis.

3. Virus rescue and characterization



[0085] Excision of the adenovirus genome from the cosmids obtained in step 2, and transfection into 293 or 293-Cymr or A549 cells. Three virus plaques per construct were harvested and amplified in small scale. Their identity will be verified by restriction analysis of their genome using 3 enzymes (Hirt supernatant).

4. Western Blot



[0086] Expression of the various transgenes from the viruses were assessed by infecting a reporter cell line with the various virus clones, lysing the cells 24 hours post-infection, separating the total protein content by PAGE, and performing western blottings (WB), anti-TIMP2, and anti-PADI1 antibodies to detect the various transgene products by chemiluminescence. These experiments will enable the selection of virus clones for amplification and purification.

5. Small-scale amplification



[0087] Small-scale amplification of the viral clones, purification on two CsCI gradients, dialysis against an isotonic buffer (GTS buffer: 2.5% glycerol, 25 mM NaCl, 20 mM Tris-HCI, pH 8.0), filtration through a low-protein binding 0.22 µm filter, and virus particle (VP) concentration determination by ultraviolet absorbance (Abs260-SDS method) was carried out.

6. Confirmation of virus identity by sequencing



[0088] The identity of the purified recombinant adenoviruses was confirmed by sequencing regions of the virus genomes specific for these recombinant viruses, including the 24-bp deletion in the E1A CDS, the entire mono- or dicistronic cassettes inserted into the E3 region, the Ad5/3 hybrid fiber, and the junctions between the DNA fragments ligated to each other during the cosmid construction. Experimental sequences were assembled into contigs and aligned with the expected sequences of the viruses.

[0089] Viral genomic DNAs were extracted from CsCl-purified virus particles using proteinase K and resuspended into 30 µL TE pH 7.5. Their quality was assessed by spectrophotometry (Abs260/280/320 nm) and agarose gel electrophoresis. TGX viruses' DNAs were sent to a third party for shotgun library making and sequencing. Libraries were generated using a Nextera XT kit (Illumina, Inc). They were pooled, quantified by qPCR, and sequenced on a 2x300 MiSeq run (Illumina, Inc) .fastq files were processed using the program "BWA Aligner". The software Geneious v11.1.5 (Biomatters Ltd) was used to visualize the .bam files and calculate the consensus sequences. The consensus sequences were aligned to the predicted sequences of the virus genomes using the software SnapGene v4.2.6.

7. Titration of the viral suspension



[0090] Titration of the viral suspension: determination of the concentration of infectious units per mL virus suspension was performed by TCID50 assay.

Cloning of TGX-07 (Ad5/3-D24-TIMP2) in more detail



[0091] To construct, amplify, purify, titrate and characterize an oncolytic adenovirus vector characterized by the following features:
  • 24-bp deletion in E1A CR2
  • a sequence encoding TIMP2 embedded into the E3 region
  • a hybrid Ad5/3 fiber


[0092] Recombinant adenovirus TGX07 was constructed by reconstituting its entire genome in a cosmid (pTGX07). The following 3 DNA fragments were ligated to each other:
  1. 1. The 27 kb Pacl-Spel fragment from pAd5/3-d24-WTE3
  2. 2. The 8587 bp Spel-Pacl fragment from pTGX106
  3. 3. The 8 kb Pacl fragment from pAd5dSfi


[0093] Where:
  • pAd5/3-d24-WTE3 (pAd5/3-d24-GMCSF)
  • pTGX106 is a plasmid that contains the right end of the virus genome (Spel-Pacl sequence from pAd5/3.d24-WTE3) with the TIMP2 coding sequence inserted between the BsiWI and Mfel sites in the E3 region
  • pAd5dSfil is a cosmid that contains the entire Ad5 genome. The 8 kb Pacl fragment provides the cosmid backbone for pTGX07
pTGX106 was constructed by inserting the 824 bp BsiWI-Notl DNA fragment from pAd1129-TIMP2 between the corresponding sites of pTGX101:
Where:
  • pTGX101 is a plasmid that contains the right end of the Ad5/3.d24-WTE3 genome (Spel-Pacl fragment from pAd5/3.d24-WTE3)
  • pAd1129-TIMP2 is a shuttle plasmid that contains the TIMP2 coding sequence between the BsiWI and Mfel site in the E3 region
pAd1129-TIMP2 was constructed by inserting a 684 bp synthetic dsDNA encoding TIMP2 between the BsiWI and Mfel sites of pAd1129-14

[0094] Where:
  • pAd1129-14 is a shuttle plasmid containing the WT Ad5 E3 region and a hybrid Ad5/3 fiber
  • gBlock-TIMP2 (GenBank # NM_003255.4)

Cloning of TGX-09 (Ad5/3-D24-PADI1) in more detail



[0095] To construct, amplify, purify, titrate and characterize an oncolytic adenovirus vector characterized by the following features:
  • 24-bp deletion in E1A CR2
  • a sequence encoding PADI1 embedded into the E3 region
  • a hybrid Ad5/3 fiber


[0096] Recombinant adenovirus TGX09 was constructed by reconstituting its entire genome in a cosmid (pTGX09). The following 3 DNA fragments were ligated to each other:
  1. 1. The 27 kb Pacl-Spel fragment from pAd5/3-d24-WTE3
  2. 2. The 9916 bp Spel-Pacl fragment from pTGX107
  3. 3. The 8 kb Pacl fragment from pAd5dSfi


[0097] Where:
  • pAd5/3-d24-WTE3 (pAd5/3-d24-GMCSF)
  • pTGX107 is a plasmid that contains the right end of the virus genome (Spel-Pacl sequence from pAd5/3.d24-WTE3) with the PADI1 coding sequence inserted between the BsiWI and Mfel sites in the E3 region
  • pAd5dSfil is a cosmid that contains the entire Ad5 genome. The 8 kb Pacl fragment provides the cosmid backbone for pTGX09
pTGX107 was constructed by inserting the 2153 bp BsiWI-Notl DNA fragment from pAd1129-PADI1 between the corresponding sites of pTGX101:
Where:
  • pAd1129-14 is a shuttle plasmid containing the WT Ad5 E3 region and a hybrid Ad5/3 fiber
  • gBlock-PADI1 (GenBank # AB033768.2)

Cloning of TGX-10 (Ad5/3-D24-PADI1-TIMP2) in more detail



[0098] To construct, amplify, purify, titrate and characterize an oncolytic adenovirus vector characterized by the following features:
  • 24-bp deletion in E1A CR2
  • a dicistronic cassette expressing PADI1 and TIMP2 embedded into the E3 region
  • a hybrid Ad5/3 fiber


[0099] Recombinant adenovirus TGX10 was constructed by reconstituting its entire genome in a cosmid (pTGX10). The following 3 DNA fragments were ligated to each other:
  1. 1. The 27 kb Pacl-Spel fragment from pAd5/3-d24-WTE3
  2. 2. The 10642 bp Spel-Pacl fragment from pTGX109b
  3. 3. The 8 kb Pacl fragment from pAd5dSfi


[0100] Where:
  • pAd5/3-d24-WTE3 (pAd5/3-d24-GMCSF)
  • pTGX109b is a plasmid that contains the right end of the virus genome (Spel-Pacl sequence from pAd5/3.d24-WTE3) with the PADI1-P2A-TIMP2 cassette inserted between the BsiWI and Mfel sites in the E3 region
  • pAd5dSfil is a cosmid that contains the entire Ad5 genome. The 8 kb Pacl fragment provides the cosmid backbone for pTGX10
pTGX109b was constructed by inserting the 2879 bp BsiWI-Notl DNA fragment from pTGX109 between the corresponding sites of pTGX101:
Where:
  • pTGX101 is a plasmid that contains the right end of the Ad5/3.d24-WTE3 genome (Spel-Pacl fragment from pAd5/3.d24-WTE3)
  • pTGX109 is a plasmid that contains the PADI-P2A-TIMP2 cassette between the BsiWI and Mfel site in the Ad5 E3 region
pTGX109 was constructed by ligating the following 4 DNA fragments to each other:
  1. 1. The 4143 bp BsiWI-Sfil fragment from pAd1129-TIMP2
  2. 2. The 1823 bp Sfil fragment from pAd1129-TIMP2
  3. 3. The 2536 bp Sfil-Mfel fragment from pAd1129-PADI1
  4. 4. A 106 bp PCR fragment encompassing a P2A element, obtained using annealed oligonucleotides (288-13 + 288-14) as template, and primers 288-15 and 288-16


[0101] Where:
  • pAd1129-TIMP2 and pAd1129-PADI1 were made for the construction of viruses TGX07 and TGX09, respectively

Primers:



[0102] 



288-15: AATGGTGGAACATGGTGCCCGGCAGCGGCGCCACTAACTT

288-16: GTGCGGGCCGCGGCGCCCATAGGCCCGGGGTTTTCTTCAA


Cloning of TGX-12 (Ad5/3-D24-PADI1-TIMP2) in more detail



[0103] To construct, amplify, purify, titrate and characterize an oncolytic adenovirus vector characterized by the following features:
  • 24-bp deletion in E1A CR2
  • a dicistronic cassette expressing PADI1 and TIMP2 in place of the E3 region (2.7 kb BgIII deletion)
  • a hybrid Ad5/3 fiber


[0104] Recombinant adenovirus TGX12 was constructed by reconstituting its entire genome in a cosmid (pTGX12). The following 3 DNA fragments were ligated to each other:
  1. 1. The 27 kb Pacl-Spel fragment from pAd5/3-d24-WTE3
  2. 2. The 10391 bp Spel-Pacl fragment from pTGX111c
  3. 3. The 8 kb Pacl fragment from pAd5dSfi


[0105] Where:
  • pAd5/3-d24-WTE3 (pAd5/3-d24-GMCSF)
  • pTGX111c is a plasmid that contains the right end of the virus genome (Spel-Pacl sequence from pAd5/3.d24-WTE3) with the CMV-PADI1-IRES-TIMP2 cassette inserted in place of the E3 region.
  • pAd5dSfil is a cosmid that contains the entire Ad5 genome. The 8 kb Pacl fragment provides the cosmid backbone for pTGX12
pTGX111c was constructed by ligating the following 3 DNA fragments to each other:
  1. 1. the 1349 bp Csil-Rsrll fragment from pTGX101
  2. 2. the 6784 bp Rsrll-Sphl fragment from pTGX101
  3. 3. the 4837 bp Sphl-Csil fragment from pTGX111b


[0106] Where:
  • pTGX101 is a plasmid that contains the right end of the Ad5/3.d24-WTE3 genome (Spel-Pacl fragment from pAd5/3.d24-WTE3)
  • pTGX111b is a plasmid that contains the CMV-PADI1-IRES-TIMP2-SV40pA signal cassette in place of the E3 region (2.7 kb BgIII deletion)
pTGX111b was constructed by digesting pTGX111 with Spel, filling-in the sticky ends with Klenow, and religating both fragments with each other, in order to destroy the Spel sites flanking the CMV-PADI1-IRES-TIMP2 cassette

[0107] Where:
  • pTGX111 is a plasmid that contains the CMV-PADI1-IRES-TIMP2-SV40pA signal cassette in place of the E3 region (2.7 kb BgIII deletion)
pTGX111 was constructed by inserting the following 4 fragments between the Sacll and Acc65I sites of pAd1129-GrB-F:
  1. 1. the 2018 bp PADI1 coding sequence amplified by PCR using pAd1129-PADI1 as template and primers 288-22 and 288-42,
  2. 2. the 645 bp IRES-att element amplified by PCR using pAd1129-IRES-att as template and primers 288-23 and 288-24,
  3. 3. the 669 bp TIMP2 coding sequence isolated from plasmid pAd1129-TIMP2 by BsiWI/Mfel digestion
  4. 4. the 174 bp SV40pA signal amplified by PCR using pAd1129-GrB-F as template and primers 288-21 and 288-25


[0108] Where:
  • pAd1129-PADI1 was made for the construction of TGX09
  • pAd1129-TIMP2 was made for the construction of TGX07
  • pAd1129-GrB-F was made for the construction of TGX01
pAd1129-IRES-att is a plasmid that contains an attenuated version of the EMCV Internal Ribosome Entry Site (IRES)

Primers:



[0109] 

288-21: TAGTTAAAGGGAATAAGATCGGTACC

288-22:

288-23: GGTGGAACATGGTGCCCTGACCCCTCTCCCTCCCCCCCCT

288-24: GTGCGGGCCGCGGCGCCCATGTCGACTCTAGAGGATCCCG

288-25: TCGACATCGAGGACCCATAAAACTTGTTTATTGCAGCTTA

288-42: TCAGGGCACCATGTTCCACCATTTG


Cell lines



[0110] Melanoma cell lines, A2058 (ATCC® CRL-1147™), A375 (ATCC® CRL-1619™) and SK-Mel-28 (ATCC® HTB-72™), were cultured in DMEM high glucose medium supplemented with 10% FCS and penicillin/streptomycin. Trypsin-EDTA was used to detach and subculture cells at 80% confluence for in vitro assays. Phosphate-buffered (PBS)-EDTA (10 mM) was used to detach A2058 melanoma cells before suspension of 20 x 106 cells in isotonic PBS for subcutaneous injection.

Data analyses



[0111] All parameters were analyzed using GraphPad Prism software (version 7). Statistical analyses have been performed using RM-one-way ANOVA followed by a Tukey post-test or T test (Mann Whitney Test). Therapeutic synergy was assessed with the FTV calculation method. FTV (mean tumor volume experimental)/(mean tumor volume control). Expected: (Mean FTV of TGX-07) x (mean FTV of TGX-09). Ratio: expected FTV by the observed FTV. A ratio of >1 indicates a synergistic effect, and a ratio of <1 indicates a less than additive effect.

EXAMPLE 1 In vitro - cell viability assay (MTS)



[0112] Cell viability was evaluated by using the MTS Cell Proliferation Assay kit (Abcam) according to the manufacturer's instructions with the following modifications. MTS assay kit is a colorimetric method for the sensitive quantification of viable cells. It can be used to assess cell proliferation, cell viability and cytotoxicity. The MTS assay is based on the reduction of the MTS tetrazolium compound by viable mammalian cells to generate a colored formazan dye that is soluble in cell culture media. This conversion is thought to be carried out by NAD(P)H-dependent dehydrogenase enzymes in metabolically active cells. The formazan dye is quantified by measuring the absorbance at 490 nm. Cells were seeded in 96 well plate at a concentration of 3000 and 5000 cells/well. Treatment was initiated in a final volume of 200µL. Cells were incubated with and without 0.1, 1, 10, 100 and 1000 viral particles (VP) of tested virus or mix of viruses. 72 hours later, MTS assay was performed according to manufacturer protocol. The plates were shaken briefly on a shaker and absorbance measured at 490 nm. Absorbance values for untreated cells were set to correspond to 100% viability, and viability of treated cells was expressed as a percentage of the untreated control absorbance value.

[0113] In in vitro cell viability assay (MTS), double transgene virus coding for PADI1 and TIMP2 (TGX-12) showed anti-cancer superiority when administered at the concentration of 1000VP/cell (46,9 % of untreated cells) over singe transgene viruses TGX-07 (coding for TIMP-2, 68,93%) and TGX-09 (coding for PADI1, 57,56%) in vitro against SK-MEL-28 cell line. Importantly, the double transgene virus showed stronger anticancer effect than the combinatory therapy of TGX-07 plus TGX-09 (61,43%), (Figure 8a). Sign of double transgene anti-cancer superiority was also reported at lower concentration (10VP/cell), where double transgene exhibited stronger anti-cancer effect over single transgene viruses (Figure 8b).

[0114] Second construct coding for double transgenes (TGX-10) also exhibited stronger anti-cancer effect at the concentration of 1 VP/cell than single transgene viruses: TGX-07, TGX-09 and combinatory treatment: TGX-07 plus TGX-09 (respectively: 74,69; 86,05; 96,71 and 94,72 % of untreated cells) in A2058 cell line (Figure 9a). 10-fold higher concentration of the treatment (10VP/cell) also resulted in enhanced and superior efficacy of the virus TGX-10 over TGX-07, TGX-09 and combinatory treatment: TGX-07 plus TGX-09 in A375 cell line (respectively: 84,61; 89,09; 102,19 and 90,11 % of untreated cells) (Figure 9b).

EXAMPLE 2 Animal studies - Immunodeficient xenograft A2058 melanoma mouse model



[0115] The study was carried out by TransCure bioServices SAS (TCS) at Archamps, France with 8-week-old female homozygous BALB/c nu/nu mice (provided by Charles River).

[0116] All animal experiments described in this study were reviewed and approved by the local ethic committee (CELEAG). Mice were hosted by groups of 6 individuals in TCS BSL-2 animal facility. Each mouse was uniquely identified. Animals were housed in a ventilated cage (type II 16x19x35 cm, floor area = 500 cm2) under the following controlled conditions:
  • Room temperature (22 ± 2°C)
  • Hygrometry (55 ± 10%)
  • Photoperiod (12:12-hour light-dark cycle 7 am to 7 pm)
  • Water and food (Ref. 2018, Harlan France) available ad libitum

Cell inoculation



[0117] A2058 cell line (ATCC® CRL-11147™) was grown in DMEM medium supplemented with 10% FBS and 1% Penicillin/Streptomycin for 4 passages and detached with Trypsin-EDTA solution at 37°C for 2 min. After washing steps, cells were suspended in PBS at a concentration of 20x106 cells/ml. 100 µl of the cell suspension (2x106 cells) were injected subcutaneously in both flanks of each mouse (100 µl of cell suspension/flank).

Randomization



[0118] Treatments were initiated the day after randomization (D1) and then continued at D3, D5, D12, D19 and D26. Mice were randomized into the following groups:
  • Mock (n=8 mice) was treated with PBS. 50 µL of PBS were injected intratumorally into both tumors.
  • Mice were treated with double transgene TGX-10 oncolytic virus (n=8 mice). Each mouse received 5x106 VP (2.5x106 VP/tumor/50 µL). 50 µL of solution 2 were injected intratumorally into both tumors.
  • Mice were treated with double transgene TGX-12 oncolytic virus (n=8 mice). Each mouse received 5x106 VP (2.5x106 VP/tumor/50 µL). 50 µL of solution 2 were injected intratumorally into both tumors.
  • Mice were treated with single transgene TGX-07 oncolytic virus (n=8 mice). Each mouse received 5x106 VP (2.5x106 VP/tumor/50 µL). 50 µL of solution 2 were injected intratumorally into both tumors.
  • Mice were treated with single transgene TGX-09 oncolytic virus (n=8 mice). Each mouse received 5x106 VP (2.5x106 VP/tumor/50 µL). 50 µL of solution 2 were injected intratumorally into both tumors.
  • Mice were treated with a mix of single transgene viruses: TGX-07 plus TGX-09 oncolytic viruses (n=8 mice). Each mouse received 5x106 VP (2.5x106 VP/tumor/50 µL). 50 µL of solution 2 were injected intratumorally into both tumors.

Read-outs



[0119] Mice were monitored daily for unexpected signs of distress. Body weight and tumor volume were monitored 3 times per week until sacrifice. Tumor volumes were measured using a digital caliper. Tumor volumes (in mm3) were calculated according to the following formula: Volume = π/6 x width2 x length.

[0120] Tumor volumes were measured over time and significant differences between groups were observed (Right tumors: TGX-12 vs TGX-07: p=0,007; TGX-12 vs TGX-09: p=0,0012; TGX-12 vs TG-07 plus TGX-09: p=0,0283; Left tumors: TGX-07 vs TGX-07 plus TGX-09: p=0,0081; TGX-09 vs TGX-07 plus TGX-09: p= 0,0167; Both tumors: TGX-12 vs TGX-07: p= 0,0076; TGX-12 vs TGX-09: p= 0,003; TGX-07 vs TGX-07 plus TGX-09: p=0,002; TGX-09 vs TGX-07 plus TGX-09: p<0,0001) (Figures 10a, 10b and 10c).

[0121] Double transgenes viruses (TGX-10 and TGX-12) and combinatory therapy: TGX-07 plus TGX-09 showed the best anticancer properties in terms of tumor volume reduction comparing to mock and single transgene viruses (TGX-07 and TGX-09) (Figure 10c). Mice treated with TGX-12 and TGX-07 plus TGX-09 maintained the right tumor volumes below 500 mm3 for all animals until the end of the experiment (Figure 10a).

[0122] Double transgene viruses TGX-10 and TGX-12 along with TGX-07 plus TGX-09 viruses showed synergistic effect as the they were able to reduce the tumor volume to a greater extent rather than viruses expressing single transgenes TGX-07 and TGX-09 (Table 2).

[0123] Body weight was monitored three times per week after tumor cell inoculation. Figure 10d shows body weight after tumor cell engraftment. For all groups, the body weight decreased after the initiation of the treatment. The treatment was well tolerated.




EXAMPLE 3 Animal studies - humanized melanoma A2058 huNOG model



[0124] NOD/Shi-scid/IL-2Rynull immunodeficient (NOG) mice received chemical myoablative treatment and were reconstituted with human stem cells by intravenous injection of one of six cord blood-derived CD34+ hematopoietic stem and progenitor cells (60,000 cells per mouse; French Blood Bank, anonymized). After these injections, flow cytometry (Atune, Life Technologies) was used to assess the composition of the human CD45+ leukocytes in the blood. Humanization rate was defined as the ratio of circulating CD45+/total CD45+ (mCD45 and hCD45).

[0125] Humanized NOG mice were injected subcutaneously in each flank with 0.1 mL suspension containing 2x106 A2058 melanoma cells. Mice were randomized based on tumor size (left and right) and humanization rate. Tumor dimensions (length (L) and width (W)) were measured three times per week with calipers and volumes calculated by using the formula (L x W2/2). Mice were treated intratumorally according to the Table 1. Body weight was also measured before the tumor engraftment and three times per week after engraftment.

[0126] All animal studies were reviewed and approved by the local ethics committee (01_TransCureBioServices-AB-01). Three to five mice were housed in ventilated type II cages (16 x 19 x 35 cm, 500 cm2 floor area) at room temperature (22 ± 2ºC), 55 ±10% humidity, 12/12-hour light-dark cycles (light 7 AM to 7 PM) and water and food ad libitum.
Table 1. Treatment schedule.
Cell lineTreatmentNumber of miceTreatment days
A2058 Inoculated s.c. both flanks at 2millions/flank Mock 8 1, 3, 5 (i.t. both tumors) and later on, every 7 days (on Days 12, 19, 26 - i.t. both tumors)
TGX-12 8
Virus dosage: 2,5x10"6 VP/50ul/tumor → VP/mouse 5x10^6 VP
TGX-07 plus TGX-09 8 1, 3, 5 (i.t. both tumors) and later on, every 7 days (on Days 12, 19, 26 - i.t. both tumors)
Virus dosage: 1,25x10^6 VP/50ul/tumor of TG0X7 plus 1,25x10^6 VP/50ul/tumor of TG0X9 and → VP/mouse 5x10^6 VP
A2058 Inoculated s.c. into right flank; later on, on Day 19 left tumor will be inoculated at 0,5million/flank TGX-12 (rechallenge) 8 1, 3, 5 (i.t. right tumor) and later on, every 7 days (on Days 12, 19, 26 - i.t. right tumor). Left tumor will not be treated
Virus dosage: 2,5x10^6 VP/50ul/right tumor → VP/mouse 5x10^6 VP
A2058 Inoculated s.c. both flanks at 2millions/flank TGX-12 6 1, 3, 5 (i.t. both tumors) and later on, every 7 days (on Days 12, 19, 26, 33 and 40 - i.t. both tumors)
Virus dosage: 0,5x10^8 VP/50ul/tumor → VP/mouse 1x10^9 VP


[0127] Double transgene virus (TGX-12) at both concentrations (5x107 (464 mm3 on Day 28) and 1x1010 VP/mL (275 mm3 on Day 28)) and combinatory therapy: TGX-07 plus TGX-09 (5x107 V/mL (488 mm3 on Day 28)) showed anticancer properties in terms of volume reduction comparing to mock (740 mm3 on Day 28) in humanized A2058 mouse model (Figure 11c). Dose-dependent effect of TGX-12 was observed, mice treated with higher concentration had greater tumor reduction (Figure 11a, 11b, 11c). The effect of double transgene virus (464 mm3 on Day 28) compared to combinatory therapy: TGX-07 plus TGX-09 (488 mm3 on Day 28) were comparable, however greater anti-cancer superiority was observed for the double transgene virus (Figure 11a, 11b, 11c).

[0128] Mice treated with TGX-12 (5x107 VP/mL) into only right flank, showed abscopal effect as the re-challenged tumor on the left flank on 3-week time point exhibited inhibited, low kinetic growth (35 mm3 on Day 42) most likely due to development of protective immune memory cells (Figures 12a and 12b).

REFERENCES



[0129] 

Bourboulia, D., Han, H., Jensen-Taubman, S., Gavil, N., Isaac, B., Wei, B., Neckers, L. & Stetler-Stevenson, W. G. 2013. TIMP-2 modulates cancer cell transcriptional profile and enhances E-cadherin/beta-catenin complex expression in A549 lung cancer cells. Oncotarget, 4, 166-76.

Feun, L. & Savaraj, N. 2006. Pegylated arginine deiminase: a novel anticancer enzyme agent. Expert Opin Investig Drugs, 15, 815-22.

Jahani, M., Noroznezhad, F. & Mansouri, K. 2018. Arginine: Challenges and opportunities of this two-faced molecule in cancer therapy. Biomed Pharmacother, 102, 594-601.

Park, I. S., Kang, S. W., Shin, Y. J., Chae, K. Y., Park, M. O., Kim, M. Y., Wheatley, D. N. & Min, B. H. 2003. Arginine deiminase: a potential inhibitor of angiogenesis and tumour growth. Br J Cancer, 89, 907-14.

Seo, D.-W., Li, H., Guedez, L., Wingfield, P. T., Diaz, T., Salloum, R., Wei, B.-Y. & Stetler-Stevenson, W. G. 2003. TIMP-2 Mediated Inhibition of Angiogenesis. Cell, 114, 171-180.


































































































































































































Claims

1. An oncolytic adenoviral vector comprising an adenovirus serotype 5 (Ad5) nucleic acid backbone, a 24 bp deletion (D24) in the Rb binding constant region 2 of E1, a nucleic acid sequence encoding a peptidylarginine deiminase and a nucleic acid sequence encoding TIMP in the E3 region.
 
2. The oncolytic adenoviral vector according to claim 1, wherein peptidylarginine deiminase and TIMP are connected with IRES.
 
3. The oncolytic adenoviral vector according to claim 1, wherein peptidylarginine deiminase and TIMP are connected with P2A.
 
4. The oncolytic adenoviral vector according to any one of claims 1-3, wherein peptidylarginine deiminase and TIMP are placed under E3 promoter.
 
5. The oncolytic adenoviral vector according to any one of claims 1-3, wherein peptidylarginine deiminase and TIMP are placed under CMV(Cuo) promoter.
 
6. The oncolytic adenoviral vector according to any one of claims 1-5, wherein peptidylarginine deiminase is PADI1 and TIMP is TIMP2.
 
7. The oncolytic adenoviral vector according to any one of claims 1-6 comprising a native E1 A promoter.
 
8. The oncolytic adenoviral vector according to any one of claims 1-7 further comprising an Ad5/3 chimerism as a capsid modification.
 
9. The oncolytic adenoviral vector according to any one of claims 1-2 or 4-8 comprising a nucleotide sequence having at least 70% identity to SEQ ID NO: 1 or according to any of claims 3-4 or 5-8 comprising a nucleotide sequence having at least 70% identity to SEQ ID NO:2.
 
10. A cell comprising the adenoviral vector according to any one of claims 1-9.
 
11. A pharmaceutical composition comprising the adenoviral vector according to any one of claims 1-9.
 
12. The adenoviral vector according to any one of claims 1-9 for use in the treatment of cancer or in the manufacture of a medicament for treating cancer in a subject.
 
13. The adenoviral vector for use according to claim 12, wherein the cancer is selected from a group consisting of nasopharyngeal cancer, synovial cancer, hepatocellular cancer, renal cancer, cancer of connective tissues, melanoma, lung cancer, bowel cancer, colon cancer, rectal cancer, colorectal cancer, brain cancer, throat cancer, oral cancer, liver cancer, bone cancer, pancreatic cancer, choriocarcinoma, gastrinoma, pheochromocytoma, prolactinoma, T-cell leukemia/lymphoma, neuroma, von Hippel-Lindau disease, Zollinger-Ellison syndrome, adrenal cancer, anal cancer, bile duct cancer, bladder cancer, ureter cancer, brain cancer, oligodendroglioma, neuroblastoma, meningioma, spinal cord tumor, bone cancer, osteochondroma, chondrosarcoma, Ewing's sarcoma, cancer of unknown primary site, carcinoid, carcinoid of gastrointestinal tract, fibrosarcoma, breast cancer, Paget's disease, cervical cancer, colorectal cancer, rectal cancer, esophagus cancer, gall bladder cancer, head cancer, eye cancer, neck cancer, kidney cancer, Wilms' tumor, liver cancer, Kaposi's sarcoma, prostate cancer, lung cancer, testicular cancer, Hodgkin's disease, non-Hodgkin's lymphoma, oral cancer, skin cancer, mesothelioma, multiple myeloma, ovarian cancer, endocrine pancreatic cancer, glucagonoma, pancreatic cancer, parathyroid cancer, penis cancer, pituitary cancer, soft tissue sarcoma, retinoblastoma, small intestine cancer, stomach cancer, thymus cancer, thyroid cancer, trophoblastic cancer, hydatidiform mole, uterine cancer, endometrial cancer, vagina cancer, vulva cancer, acoustic neuroma, mycosis fungoides, insulinoma, carcinoid syndrome, somatostatinoma, gum cancer, heart cancer, lip cancer, meninges cancer, mouth cancer, nerve cancer, palate cancer, parotid gland cancer, peritoneum cancer, pharynx cancer, pleural cancer, salivary gland cancer, tongue cancer and tonsil cancer.
 
14. The adenoviral vector for use according to claim 12 or 13, wherein the treatment of cancer in a subject is conducted through an intratumoral, intramuscular, intra-arterial, intravenous, intrapleural, intravesicular, intracavitary or peritoneal injection, or an oral administration.
 
15. The adenoviral vector for use according to claim 14, wherein the injection or the administration is conducted several times during the treatment period, or wherein an oncolytic adenoviral vector having a different fiber knob of the capsid compared to the vector of the earlier treatment is used.
 
16. The adenoviral vector for use according to any one of claims 12-15, wherein the treatment of cancer in a subject further comprises an administration of a checkpoint inhibitor, verapamil or another calcium channel blocker, autophagy inducing agents, temozolomide, chemotherapy or anti-CD20 therapy or other approaches for blocking of neutralizing antibodies, substances capable to downregulating regulatory T-cells in a subject to a subject.
 
17. A method of producing peptidylarginine deiminase and TIMP in a cell in vitro, wherein the method comprises:

i. carrying a vehicle comprising an oncolytic adenoviral vector according to any one of claims 1-9 to a cell, and

ii. expressing peptidylarginine deiminase and TIMP of said vector in the cell.


 
18. A use of the oncolytic adenoviral vector according to any one of claims 1-9 for producing peptidylarginine deiminase and TIMP in a cell in vitro.
 




Drawing














































Search report









Search report




Cited references

REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description